Er Therapeutics Valuation
| PNGM Stock | USD 0.0001 0.00 0.000003% |
Er Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Er Therapeutics from reviewing the firm fundamentals such as Cash And Equivalents of 650, current valuation of 122.36 K, and Price To Book of 143,650 X as well as analyzing its technical indicators and probability of bankruptcy.
Price Book 143.7 K | Enterprise Value 122.4 K | Enterprise Value Ebitda (0.25) |
Overvalued
Today
Please note that Er Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Er Therapeutics is based on 3 months time horizon. Increasing Er Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the PNGM stock is determined by what a typical buyer is willing to pay for full or partial control of Er Therapeutics. Since Er Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of PNGM Stock. However, Er Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 | Naive 1.0E-4 |
The intrinsic value of Er Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Er Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Er Therapeutics helps investors to forecast how PNGM stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Er Therapeutics more accurately as focusing exclusively on Er Therapeutics' fundamentals will not take into account other important factors: Er Therapeutics Cash |
|
Er Therapeutics Total Value Analysis
Er Therapeutics is at this time forecasted to have valuation of 122.36 K with market capitalization of 332.11 K, debt of 48.49 K, and cash on hands of 650. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Er Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
122.36 K | 332.11 K | 48.49 K | 650 |
Er Therapeutics Asset Utilization
One of the ways to look at asset utilization of PNGM is to check how much profit was generated for every dollar of assets it reports. Er Therapeutics owns a negative utilization of current and long term assets of -0.95 %, losing $0.009491 for each dollar of current and long term assets held by the firm. Discouraging asset utilization denotes the company is being less productive with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of Er Therapeutics shows how wasteful it operates for each dollar spent on its current and long term assets.Er Therapeutics Profitability Analysis
Net Loss for the year was (426.95 K) with profit before overhead, payroll, taxes, and interest of 0.About Er Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Er Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Er Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Er Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Er Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Er Therapeutics. We calculate exposure to Er Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Er Therapeutics's related companies. When determining whether Er Therapeutics is a strong investment it is important to analyze Er Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Er Therapeutics' future performance. For an informed investment choice regarding PNGM Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Er Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in PNGM Stock, please use our How to Invest in Er Therapeutics guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Diversified Metals & Mining space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Er Therapeutics. If investors know PNGM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Er Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.95) |
The market value of Er Therapeutics is measured differently than its book value, which is the value of PNGM that is recorded on the company's balance sheet. Investors also form their own opinion of Er Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Er Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Er Therapeutics' market value can be influenced by many factors that don't directly affect Er Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Er Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Er Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Er Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.